Targeted Oncology5m
FDA Approves Osimertinib in Stage III EGFR-Mutated NSCLC
Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...
Targeted Oncology1h
Exploring High Sensitivity ctDNA Assays in Genitourinary Malignancies
Arnab Basu, MD, MPH, FACP, discusses his research on high sensitivity circulating tumor DNA assays in genitourinary malignancies.
Targeted Oncology3h
Durvalumab Consolidation Extends Survival in LS-SCLC, ADRIATIC Findings Show
Missak Haigentz, MD, discussed the implications and next steps of the ADRIATIC study in patients with limited-stage small ...
Targeted Oncology5h
GLP-1 Agonists Poised to Impact Breast Cancer Care
In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...
Targeted Oncology6h
What Impact Will GLP-1 Agonists Have on Cancer?
GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...
Targeted Oncology22h
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and ...
Targeted Oncology23h
LP-184 Earns 3 FDA Rare Pediatric Disease Designations in Solid Tumors
The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...
Targeted Oncology23h
Axatilimab in Refractory/Recurrent cGVHD: A Promising Later-Line Option
Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent ...
Targeted Oncology23h
Advancing to Third-Line Therapy: Belumosudil in cGVHD
Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease ...